Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247381473> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2247381473 abstract "e19055 Background: Platinum compounds are the main component of the CT in NSCLC. Standard recommended doses of cisplatin/carboplatin is usually couldn’t be administered and dose reductions are necessary because of side effects. We aimed to determine the effect of dose reductions of platinums on outcome of stage IIIB/IV NSCLC. Methods: Data of 420 patients were retrospectively reviewed. A platinum analogue was used in combination with vinorelbine, gemcitabine, paclitaxel, docetaxel or etoposide as first line treatment in 85% patients. Cumulative platinum doses and dose reduction ratios compared to standard doses were calculated. Patients with decreased GFR were excluded from the analysis. Results: Median age was 60 years (range: 28-87), 79% of patients were male, 31% were 65 yearsold/older, 55% had PS of 0, and 27% had stage IIIB disease. Histological subtypes were squamous cell in 32%, adenocarcinoma in 34%, and NSCLC in 31%. Median dose of cisplatin used per cycle was 67mg/m2 and carboplatin was 287mg/m2. 51% of the patients received standard or less than 10% reducted doses of platinum, while dose reductions were 10–20% in 19%, 21–30% in 24% of patients, and more than 31% in 6%. Median overall survival (OS) was 11 months, 1- year and 2-year OS ratios were 56% and 25%, respectively. Median time to progression was 5 months; 1-year progression free survival ratio was 18%. Gender, age, histologic subtype, and treatment with lower dose of platinum didn’t have any statistically significant impact on survival in univariate analysis. Patients with PS of 0, no weight loss, stage IIIB disease, receiving combination CT with docetaxel-cisplatin, and having partial response to treatment lived significantly longer. On multivariate analysis weight loss, stage and type of response to treatment had an impact on OS. Conclusions: Using lower doses of platinum compounds in combination chemotherapy for stage IIIB/IV non-small cell lung cancer might not have a negative impact on survival and definitely have a better toxicity profile. No significant financial relationships to disclose." @default.
- W2247381473 created "2016-06-24" @default.
- W2247381473 creator A5018888045 @default.
- W2247381473 creator A5033738148 @default.
- W2247381473 creator A5064011743 @default.
- W2247381473 creator A5076620707 @default.
- W2247381473 creator A5078640497 @default.
- W2247381473 creator A5082587759 @default.
- W2247381473 date "2009-05-20" @default.
- W2247381473 modified "2023-09-26" @default.
- W2247381473 title "Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)" @default.
- W2247381473 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e19055" @default.
- W2247381473 hasPublicationYear "2009" @default.
- W2247381473 type Work @default.
- W2247381473 sameAs 2247381473 @default.
- W2247381473 citedByCount "0" @default.
- W2247381473 crossrefType "journal-article" @default.
- W2247381473 hasAuthorship W2247381473A5018888045 @default.
- W2247381473 hasAuthorship W2247381473A5033738148 @default.
- W2247381473 hasAuthorship W2247381473A5064011743 @default.
- W2247381473 hasAuthorship W2247381473A5076620707 @default.
- W2247381473 hasAuthorship W2247381473A5078640497 @default.
- W2247381473 hasAuthorship W2247381473A5082587759 @default.
- W2247381473 hasConcept C121608353 @default.
- W2247381473 hasConcept C126322002 @default.
- W2247381473 hasConcept C143998085 @default.
- W2247381473 hasConcept C146357865 @default.
- W2247381473 hasConcept C151730666 @default.
- W2247381473 hasConcept C2776256026 @default.
- W2247381473 hasConcept C3019894029 @default.
- W2247381473 hasConcept C71924100 @default.
- W2247381473 hasConcept C86803240 @default.
- W2247381473 hasConceptScore W2247381473C121608353 @default.
- W2247381473 hasConceptScore W2247381473C126322002 @default.
- W2247381473 hasConceptScore W2247381473C143998085 @default.
- W2247381473 hasConceptScore W2247381473C146357865 @default.
- W2247381473 hasConceptScore W2247381473C151730666 @default.
- W2247381473 hasConceptScore W2247381473C2776256026 @default.
- W2247381473 hasConceptScore W2247381473C3019894029 @default.
- W2247381473 hasConceptScore W2247381473C71924100 @default.
- W2247381473 hasConceptScore W2247381473C86803240 @default.
- W2247381473 hasLocation W22473814731 @default.
- W2247381473 hasOpenAccess W2247381473 @default.
- W2247381473 hasPrimaryLocation W22473814731 @default.
- W2247381473 isParatext "false" @default.
- W2247381473 isRetracted "false" @default.
- W2247381473 magId "2247381473" @default.
- W2247381473 workType "article" @default.